07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

Avac Pharma Ltd., ChronTech deal

ChronTech said newco Avac completed its acquisition of all of ChronTech's assets related to development programs for DNA vaccines against HBV and HCV. ChronTech could not be reached for details (see BioCentury, May 13 &...
07:00 , May 27, 2013 |  BC Week In Review  |  Company News

ChronTech infectious, drug delivery news

At its May 16 meeting, ChronTech's shareholders approved the transfer of all of the company's assets related to development programs for DNA vaccines against HBV and HCV to newco Avac Pharma Ltd. for $1 million....
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

ChronTech infectious, drug delivery news

ChronTech said that a group of shareholders offered to acquire all assets related to ChronTech's development programs for DNA vaccines against HBV and HCV for $1 million. The shareholders have formed newco Avac Pharma Ltd....